RedHill Biopharma
8045 Arco Corporate Drive
Suite 200
Raleigh
NC
27617
United States
Website: http://www.redhillbio.com/
479 articles about RedHill Biopharma
-
RedHill Biopharma Ltd. Initiates Phase III Study of RHB-105 for H. pylori Infection
10/30/2013
-
RedHill Biopharma Ltd. to Present at the 2013 Annual BioNetwork Conference
10/23/2013
-
RedHill Biopharma Ltd. Announces FDA Acceptance of IND Application for RHB-105 (H. pylori) Phase 3 Study - to Commence Shortly
10/22/2013
-
RedHill Biopharma Ltd.'s RHB-104 Combination Achieves 80% Remission in Independent Pediatric Crohn's Study
10/15/2013
-
RedHill Biopharma Ltd. Reports Positive PK Clinical Studies Towards Planned NDA with RHB-102 (Anti-Emetic)
10/8/2013
-
RedHill Biopharma Ltd. Initiates Phase III Study of RHB-104 for Crohn's Disease
10/1/2013
-
RedHill Biopharma Ltd. to Present at the Annual BioPharm America International Partnering Conference
9/11/2013
-
RedHill Biopharma Ltd. to Present at the Stifel Nicolaus Annual Healthcare Conference
9/3/2013
-
Bioassociate Reiterated PT on RedHill Biopharma Ltd. Following Q2 Report
8/21/2013
-
RedHill Biopharma Ltd. Announces Positive European Regulatory Meetings Regarding Its European Phase III Plan for RHB-104 (Crohn's)
8/20/2013
-
RedHill Biopharma Ltd. Announces Positive Pre-Clinical Rheumatoid Arthritis Results With RHB-104 and Plans for a Phase IIa Study
7/30/2013
-
RedHill Biopharma Ltd. Reports Results for the Second Quarter of 2013
7/23/2013
-
RedHill Biopharma Ltd. Provides Update on Planned NDA Filing for RHB-102 (Once Daily Anti-Emetic) in Q1 2014 and Commences PK Program
7/11/2013
-
RedHill Biopharma Ltd. to Present at the JMP Securities Annual Healthcare Conference in New York
7/3/2013
-
RedHill Biopharma Ltd. Announces FDA Acceptance for Review of RHB-103 NDA for Acute Migraine and PDUFA Goal Date of February 3, 2014
6/18/2013
-
RedHill Biopharma Ltd. Commences Patient Screening in a Phase IIa Clinical Trial With RHB-104 for Multiple Sclerosis
6/5/2013
-
RedHill Biopharma Ltd. Announces Positive FDA Meeting Regarding the Regulatory Path Towards NDA Submission of RHB-101 for the Treatment of Congestive Heart Failure and Hypertension
5/29/2013
-
RedHill Biopharma Ltd. to Present at the Jefferies and Co. 2013 Global Healthcare Conference in New York
5/28/2013
-
RedHill Biopharma Ltd. Submits New Drug Application to U.S. FDA for RHB-103 Anti-Migraine Oral Thin Film
3/27/2013
-
RedHill Biopharma Ltd. Receives Positive Feedback From a Scientific Advice Meeting in Europe Regarding RHB-101 (Hypertension) Marketing Application Plan
3/19/2013